<DOC>
	<DOCNO>NCT00005073</DOCNO>
	<brief_summary>RATIONALE : Zoledronate may able prevent bone metastasis cause prostate cancer . It yet know zoledronate effective prevent spread prostate cancer bone . PURPOSE : Randomized phase III trial determine effectiveness zoledronate plus standard therapy prevent bone metastases patient recurrent prostate cancer cause symptom .</brief_summary>
	<brief_title>Zoledronate Plus Standard Therapy Compared With Placebo Plus Standard Therapy Prevent Bone Metastases Patients With Recurrent Prostate Cancer That Has No Symptoms</brief_title>
	<detailed_description>OBJECTIVES : I . Compare bone metastases free overall survival patient asymptomatic recurrent prostate cancer treat zoledronate v placebo different time point . II . Compare time first skeletal related event ( pathological fracture , surgery prevent treat pathological fracture , spinal cord compression , radiotherapy bone ) skeletal morbidity rate patient treat 2 regimen . III . Assess quality life pain patient treat 2 regimen . OUTLINE : This randomize , double blind , placebo control , open label , multicenter study . Patients stratify prior local treatment ( noncurative v curative ) time interval surgical castration initiation LHRH agonists trial entry ( less 1 year v 1-2 year vs great 2 year ) . Patients randomize 1 2 treatment arm : Arm I : Patients receive zoledronate IV 15 minute day 1 . Arm II : Patients receive placebo IV 15 minute day 1 . Both arm : Treatment repeat every 4 week absence document bone metastasis , disease progression , unacceptable toxicity . All patient document bone metastasis receive zoledronate arm I year 4 . All patient receive oral calcium oral vitamin D daily . Patients receive LHRH agonist instead surgical castration prior study continue LHRH agonist therapy study . Quality life pain assess treatment . Patients follow every 6 month . PROJECTED ACCRUAL : A total 500 patient ( 250 per arm ) accrue study .</detailed_description>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven asymptomatic recurrent prostate cancer Prior local treatment status Curatively treat OR Locally advance disease noncuratively treat LHRH agonist therapy Currently receive 1 line hormonal therapy ( LHRH agonists surgical castration ) fail treatment rise PSA Patients receive LHRH agonist instead surgical castration continue receive LHRH agonist study Biochemical progression document 3 consecutively rise PSA measurement , least 2 week apart , last measurement 50 % great nadir PSA achieve last therapeutic maneuver ( first line hormonal therapy note ) PSA ( 50 % increased value ) great 4 ng/mL patient intact prostate great 0.8 ng/mL postprostatectomy patient Rising PSA le 10 month Castrate level testosterone ( le 30 ng/dL ) No bone visceral metastasis bone scan CT scan abdomen pelvis ( except localize abnormality pelvic lymph node soft tissue disease ) No CNS leptomeningeal involvement PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 90100 % Life expectancy : Greater 6 month Hematopoietic : WBC least 3,000/mm3 Absolute neutrophil count least 1,500/mm3 Hemoglobin least 8.0 g/dL Platelet count least 75,000/mm3 Hepatic : Liver function test great 2.5 time upper limit normal ( ULN ) Renal : Creatinine great 1.5 time ULN Cardiovascular : No New York Heart Association class III IV heart disease uncontrolled and/or unstable cardiac coronary artery disease Other : No malignancy within past 5 year would confound etiology metastatic disease except curatively treat nonmelanomatous skin cancer No nonmalignant disease would confound evaluation preclude compliance Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : No prior systemic biologic anticancer therapy Chemotherapy : No prior chemotherapy Concurrent chemotherapy estramustine contain regimen mitoxantrone allow discretion protocol investigator Endocrine therapy : See Disease Characteristics No prior systemic hormonal anticancer therapy except LHRH antagonist and/or nonsteroidal antiandrogens ( e.g. , flutamide , bicalutamide , nilutamide ) Concurrent aminoglutethimide , prednisone , diethylstilbestrol estrogen allow discretion protocol investigator Radiotherapy : At least 6 week since prior palliative radiotherapy Surgery : See Disease Characteristics Other : No prior systemic anticancer therapy At least 4 week since prior investigational drug No concurrent bisphosphonate agent</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>stage I prostate cancer</keyword>
	<keyword>stage IIB prostate cancer</keyword>
	<keyword>stage IIA prostate cancer</keyword>
	<keyword>stage III prostate cancer</keyword>
	<keyword>recurrent prostate cancer</keyword>
</DOC>